Doyle Mittieinsider trades

In SEC Form 4 filings, Doyle Mittie is listed as Chief Medical Officer of Avalo Therapeutics, Inc. (AVTX). In the last 90 days, Doyle Mittie sold $13.6K of Avalo Therapeutics, Inc. (AVTX) on the open market and bought none. The sale was reported under a 10b5-1 trading plan.

Companies and roles

Company	Role	Transactions	Last filed
AVTXAvalo Therapeutics, Inc.	Chief Medical Officer	3	Sep 1

Cluster buys

No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).

Form 4 historysince 2026-09-01

Company	Traded	Filed	Type	Shares	Price	Value	Owned after	10b5-1 plan	Filing
AVTXAvalo Therapeutics, Inc.	Aug 28	Sep 1	M	679	$8.04	$5,459	52,455	Yes	Form 4
AVTXAvalo Therapeutics, Inc.	Aug 28	Sep 1	S	679	$20.00	Sale −$13,580	51,776	Yes	Form 4
AVTXAvalo Therapeutics, Inc.	Aug 28	Sep 1	M · derivative	679	$8.04	$5,459	113,734	Yes	Form 4

Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.